nach oben

Current Heart Failure Reports

Erschienen in:

01.03.2010

Galectin-3 in Cardiac Remodeling and Heart Failure

verfasst von: Rudolf A. de Boer, Lili Yu, Dirk J. van Veldhuisen

Erschienen in: Current Heart Failure Reports | Ausgabe 1/2010

Einloggen, um Zugang zu erhalten

Abstract

Galectin-3 is a member of the galectin family, which consists of animal lectins that bind β-galactosides. Recently, a role for galectin-3 in the pathophysiology of heart failure has been suggested. It was observed that galectin-3 is specifically upregulated in decompensated heart failure compared with compensated heart failure in animal models of heart failure. This has been associated with activation of fibroblasts and macrophages, which are a hallmark of cardiac remodeling. Therefore, galectin-3 may be a culprit biomarker in heart failure. Initial clinical observations indicate that galectin-3 may be a useful biomarker for decompensated heart failure, with incremental value over well-used “pressure-dependent” biomarkers, such as B-type natriuretic peptide. Future studies should focus on galectin-3 biology to better address the usefulness of galectin-3 as a biomarker and probe the usefulness of anti-galectin-3 therapy in treating heart failure.

Barondes SH, Cooper DNW, Gitt MA, Leffler H: Galectins: structure and function of a large family of animal lectins. J Biol Chem 1994, 269:20807–20810.PubMed

Cooper DN: Galectinomics: finding themes in complexity. Biochim Biophys Acta 2002, 1572:209–231.PubMedCrossRef

Wang JL, Laing JG, Anderson RL: Lectins in the cell nucleus. Glycobiology 1991, 3:243–252.CrossRef

•• Yang RY, Rabinovich GA, Liu FT: Galectins: structure, function and therapeutic potential. Expert Rev Mol Med 2008, 13:e17–e39. This excellent review article provides insight regarding galectin biology.CrossRef

Elola MT, Wolfenstein-Todel C, Troncoso MF, et al.: Galectins: matricellular glycan-binding proteins linking cell adhesion, migration, and survival. Cell Mol Life Sci 2007, 64:1679–1700.PubMedCrossRef

Liu FT, Patterson RJ, Wang JL: Intracellular functions of galectins. Biochim Biophys Acta 2002, 1572:263–273.PubMedCrossRef

Wang JL, Laing JG, Anderson RL: Lectins in the cell nucleus. Glycobiology 1991, 3:243–252.CrossRef

Hughes RC: Mac-2: a versatile galactose-binding protein of mammalian tissues. Glycobiology 1994, 4:5–12.PubMedCrossRef

Birdsall B, Feeney J, Burdett IDJ, et al.: NMR solution studies of hamster galectin-3 and electron microscopic visualization of surface-adsorbed complexes: evidence for interactions between the N-and C-terminal domains. Biochemistry 2001, 40:4859–4866.PubMedCrossRef

10.

Krześlak A, Lipińska A: Galectin-3 as a multifunctional protein. Cell Mol Biol Lett 2004, 9:305–328.PubMed

11.

Rosenberg I, Cherayil BJ, Isselbacher KJ, Pillai S: Mac-2-binding glycoproteins. Putative ligands for a cytosolic β-galactoside lectin. J Biol Chem 1991, 266:18731–18736.

12.

Sato S, Hughes RC: Binding specificity of a baby hamster kidney lectin for H type I and II chains, polylactosamine glycans, and appropriately glycosylated forms of laminin and fibronectin. J Biol Chem 1992, 267:6983–6990.PubMed

13.

Ochieng J, Furtak V, Lukyanov P: Extracellular functions of galectin-3. Glycoconj J 2004, 19:527–535.PubMedCrossRef

14.

Nakahara S, Oka N, Wang Y, et al.: Characterization of the nuclear import pathways of galectin-3. Cancer Res 2006, 66:9995–10006.PubMedCrossRef

15.

Menon RP, Hughes RC: Determinants in the N-terminal domains of galectin-3 for secretion by a novel pathway circumventing the endoplasmic reticulum-Golgi complex. Eur J Biochem 1999, 264:569–576.PubMedCrossRef

16.

Mehul B, Hughes RC: Plasma membrane targeting, vesicular budding and release of galectin 3 from the cytoplasm of mammalian cells during secretion. J Cell Sci 1997, 110:1169–1178.PubMed

17.

Hughes RC: The galectin family of mammalian carbohydrate-binding molecules. Biochem Soc Transact 1997, 25:1194–1198.

18.

Hughes RC: Secretion of the galectin family of mammalian carbohydrate-binding family proteins. Biochem Biophys Acta 1999, 1473:172–185.PubMedCrossRef

19.

Kim H, Lee J, Hyun JW, et al.: Expression and immunohistochemical localization of galectin-3 in various mouse tissues. Cell Biol Int 2007, 31:655–662.PubMedCrossRef

20.

Sharma UC, Pokharel S, van Brakel TJ, et al.: Galectin-3 marks activated macrophages in failure-prone hypertrophied hearts and contributes to cardiac dysfunction. Circulation 2004, 110:3121–3128.PubMedCrossRef

21.

Lee MA, Böhm M, Paul M, et al.: Physiological characterization of the hypertensive transgenic rat TGR(mREN2)27. Am J Physiol 1996, 270:E919–E929.PubMed

22.

de Boer RA, Pokharel S, Flesch M, et al.: Extracellular signal regulated kinase and SMAD signaling both mediate the angiotensin II driven progression towards overt heart failure in homozygous TGR(mRen2)27. J Mol Med 2004, 82:678–687.PubMedCrossRef

23.

Schroen B, Heymans S, Sharma U, et al.: Thrombospondin-2 is essential for myocardial matrix integrity: increased expression identifies failure-prone cardiac hypertrophy. Circ Res 2004, 95:515–522.PubMedCrossRef

24.

Thandavarayan RA, Watanabe K, Ma M, et al.: 14-3-3 protein regulates Ask1 signaling and protects against diabetic cardiomyopathy. Biochem Pharmacol 2008, 75:1797–1806.PubMedCrossRef

25.

Sharma U, Rhaleb NE, Pokharel S, et al.: Novel anti-inflammatory mechanisms of N-Acetyl-Ser-Asp-Lys-Pro in hypertension-induced target organ damage. Am J Physiol 2008, 294:H1226–H1232.

26.

• Liu YH, D’Ambrosio M, Liao TD, et al.: N-acetyl-seryl-aspartyl-lysyl-proline prevents cardiac remodeling and dysfunction induced by galectin-3, a mammalian adhesion/growth-regulatory lectin. Am J Physiol Heart Circ Physiol 2009, 296:H404–H412. This article evaluates anti-galectin-3 therapy and demonstrates how it may reverse adverse cardiac remodeling, providing support for the hypothesis that anti-galectin therapy may be feasible.PubMedCrossRef

27.

Friedman SL: Molecular regulation of hepatic fibrosis, an integrated cellular response to tissue injury. J Biol Chem 2000, 275:2247–2250.PubMedCrossRef

28.

Brown RD, Ambler SK, Mitchell MD, Long CS: The cardiac fibroblast: therapeutic target in myocardial remodeling and failure. Annu Rev Pharmacol Toxicol 2005, 45:657–687.PubMedCrossRef

29.

de Cavanagh EM, Ferder M, Inserra F, Ferder L: Angiotensin II, mitochondria, cytoskeletal, and extracellular matrix connections: an integrating viewpoint. Am J Physiol Heart Circ Physiol 2009, 296:H550–H558.PubMedCrossRef

30.

Hsu DK, Dowling CA, Jeng KC, et al.: Galectin-3 expression is induced in cirrhotic liver and hepatocellular carcinoma. Int J Cancer 1999, 81:519–526.PubMedCrossRef

31.

Henderson NC, Mackinnon AC, Farnworth SL, et al.: Galectin-3 regulates myofibroblast activation and hepatic fibrosis. Proc Natl Acad Sci USA 2006, 103:5060–5065.PubMedCrossRef

32.

Nishi Y, Sano H, Kawashima T, et al.: Role of galectin-3 in human pulmonary fibrosis. Allergol Int 2007, 56:57–65.PubMedCrossRef

33.

Wang L, Friess H, Zhu Z, et al.: Galectin-1 and galectin-3 in chronic pancreatitis. Lab Invest 2000, 80:1223–1241.CrossRef

34.

Sasaki S, Bao Q, Hughes RC: Galectin-3 modulates rat mesangial cell proliferation and matrix synthesis during experimental glomerulonephritis induced by anti-Thy1.1 antibodies. J Pathol 1999, 187:481–489.PubMedCrossRef

35.

• Henderson NC, Mackinnon AC, Farnworth SL, et al.: Galectin-3 expression and secretion links macrophages to the promotion of renal fibrosis. Am J Pathol 2008, 172:288–298. This experimental study underscores the pivotal role of galectin-3 in the fibrosis process. Employing galectin-3 deficient mice, the authors show that galectin-3 regulates renal fibrosis.PubMedCrossRef

36.

Eis V, Luckow B, Vielhauer V, et al.: Chemokine receptor CCR1 but not CCR5 mediates leukocyte recruitment and subsequent renal fibrosis after unilateral ureteral obstruction. J Am Soc Nephrol 2004, 15:337–347.PubMedCrossRef

37.

Vlassara H, Li YM, Imani F, et al.: Identification of galectin-3 as a high-affinity binding protein for advanced glycation end products (AGE): a new member of the AGE-receptor complex. Mol Med 1995, 1:634–646.PubMed

38.

Hartog JW, Voors AA, Bakker SJ, et al.: Advanced glycation end-products (AGEs) and heart failure: pathophysiology and clinical implications. Eur J Heart Fail 2007, 9:1146–1155.PubMedCrossRef

39.

Iacobini C, Oddi G, Menini S, et al.: Development of age-dependent glomerular lesions in galectin-3/AGE-receptor-3 knockout mice. Am J Physiol 2005, 289:F611–F621.CrossRef

40.

Iacobini C, Menini S, Oddi G, et al.: Galectin-3/AGE-receptor 3 knockout mice show accelerated AGE-induced glomerular injury: evidence for a protective role of galectin-3 as an AGE receptor. FASEB J 2004, 18:1773–1775.PubMed

41.

Frangogiannis NG: The immune system and cardiac repair. Pharmacol Res 2008, 58:88–111.PubMedCrossRef

42.

Reifenberg K, Lehr HA, Torzewski M, et al.: Interferon-gamma induces chronic active myocarditis and cardiomyopathy in transgenic mice. Am J Pathol 2007, 171:463–472.PubMedCrossRef

43.

van Kimmenade RR, Januzzi JL Jr, Ellinor PT, et al.: Utility of aminoterminal pro-brain natriuretic peptide, galectin-3, and apelin for the evaluation of patients with acute heart failure. J Am Coll Cardiol 2006, 48:1217–1224.PubMedCrossRef

44.

Milting H, Ellinghaus P, Seewald M, et al.: Plasma biomarkers of myocardial fibrosis and remodeling in terminal heart failure patients supported by mechanical circulatory support devices. J Heart Lung Transplant 2008, 27:589–596.PubMedCrossRef

45.

Lin YH, Lin LY, Wu YW, et al.: The relationship between serum galectin-3 and serum markers of cardiac extracellular matrix turnover in heart failure patients. Clin Chim Acta 2009, 409:96–99.PubMedCrossRef

46.

• de Boer RA, Voors AA, Muntendam P, et al.: Galectin-3: a novel mediator of heart failure development and progression. Eur J Heart Fail 2009, 11:811–817. This article provides a complete overview of the potential role of galectin-3 in the pathophysiology of heart failure.PubMedCrossRef

47.

Dickstein K, Cohen-Solal A, Filippatos G, et al.: ESC guidelines for the diagnosis treatment of acute, chronic heart failure 2008. The task force for the diagnosis and treatment of acute and chronic heart failure 2008 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association of the ESC (HFA) and endorsed by the European Society of Intensive Care Medicine (ESICM). Eur J Heart Fail 2008, 10:933–989.PubMedCrossRef

Titel: Galectin-3 in Cardiac Remodeling and Heart Failure
verfasst von: Rudolf A. de Boer
Lili Yu
Dirk J. van Veldhuisen
Publikationsdatum: 01.03.2010
Verlag: Springer-Verlag
Erschienen in: Current Heart Failure Reports / Ausgabe 1/2010
Print ISSN: 1546-9530
Elektronische ISSN: 1546-9549
DOI: https://doi.org/10.1007/s11897-010-0004-x

Neu im Fachgebiet Kardiologie

Ein Drittel der jungen Ärztinnen und Ärzte erwägt abzuwandern

07.05.2024 Medizinstudium Nachrichten

Extreme Arbeitsverdichtung und kaum Supervision: Dr. Andrea Martini, Sprecherin des Bündnisses Junge Ärztinnen und Ärzte (BJÄ) über den Frust des ärztlichen Nachwuchses und die Vorteile des Rucksack-Modells.

Vorhofflimmern bei Jüngeren gefährlicher als gedacht

06.05.2024 Vorhofflimmern Nachrichten

Immer mehr jüngere Menschen leiden unter Vorhofflimmern. Betroffene unter 65 Jahren haben viele Risikofaktoren und ein signifikant erhöhtes Sterberisiko verglichen mit Gleichaltrigen ohne die Erkrankung.

Chronisches Koronarsyndrom: Gefahr von Hospitalisierung wegen Herzinsuffizienz

06.05.2024 Herzinsuffizienz Nachrichten

Obwohl ein rezidivierender Herzinfarkt bei chronischem Koronarsyndrom wahrscheinlich die Hauptsorge sowohl der Patienten als auch der Ärzte ist, sind andere Ereignisse womöglich gefährlicher. Laut einer französischen Studie stellt eine Hospitalisation wegen Herzinsuffizienz eine größere Gefahr dar.

Das Risiko für Vorhofflimmern in der Bevölkerung steigt

02.05.2024 Vorhofflimmern Nachrichten

Das Risiko, im Lauf des Lebens an Vorhofflimmern zu erkranken, ist in den vergangenen 20 Jahren gestiegen: Laut dänischen Zahlen wird es drei von zehn Personen treffen. Das hat Folgen weit über die Schlaganfallgefährdung hinaus.

Update Kardiologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 1/2010

Exercise in the Management of Patients with Chronic Heart Failure

ST2: A Novel Remodeling Biomarker in Acute and Chronic Heart Failure

An Update on Cardiac Troponins as Circulating Biomarkers in Heart Failure

Percutaneous Mitral Valve Repair: Potential in Heart Failure Management